On 14 October 2026, the European Commission published minutes from the Scientific Committee on Consumer Safety (SCCS) working-group meeting held on 23–24 September. For skincare teams considering the EU market, the publication offers a dated view of ingredient assessments in progress.
The meeting record separates final-document discussions from draft opinions. Our practical reading is to use it to organise follow-up questions, then check later publications before making a formula or launch decision.
Under draft opinions, the minutes record the following positions at the September meeting:
These entries describe assessment work. They do not provide a new use limit or implementation date for a buyer's finished skincare product. The publication date of the minutes is also different from the date of the meeting they describe.
Start with the current formula and raw-material records. Ask the manufacturer for the ingredient identity, supplier grade, concentration, function and product type for any material that may be relevant. Where a trade name or blend is used, request enough composition information for the responsible technical team to make the comparison.
A similar name is a reason to investigate, not a basis for substituting ingredients. Keep the material identifier beside the relevant assessment title and explain why the team considers it a match. If identity is uncertain, record that uncertainty before discussing reformulation.
Give each watchlist entry a source link, meeting date, publication date, document status and review owner. Distinguish a meeting discussion, preliminary text and adopted opinion in the project record. Ask the regulatory or safety lead to check later SCCS publications and the applicable EU requirements separately.
This prevents a common handover problem: purchasing may be working from a recent news item while development is relying on an older technical file. Attach the review outcome to the specific formula version, intended use and target market so that a general monitoring note does not become an unsupported approval decision.
Ask the responsible team what new document or information would trigger another review. That might be a later opinion, clarification of the material identity, or updated supplier documentation. Agree who will monitor it and how the result will reach development, purchasing and the person responsible for market release.
Before requesting replacement samples, establish whether a change is needed for the actual project. If it is, evaluate the revised formula and packaging together and document the checks still required. A meeting agenda entry alone cannot establish the performance or readiness of an alternative formulation.
When reviewing the Lanthome Skincare product range, keep your EU-market questions with the proposed product format and ingredient priorities. Share a project brief that identifies the documents and technical review you need. Any product-specific conclusion requires its own evidence and responsible review.
European Commission, DG Health and Food Safety: publication announcement, 14 October 2026; minutes of the 23–24 September meeting, document dated 5 October. Sources reviewed 17 October 2026.
